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abstract: Tranylcypromine is an effective antidepressant from the class of monoamine oxidase inhibitors and 
is structurally related to amphetamine. However, reports differ regarding the potential metabolism of tranyl-
cypromine to amphetamine and methamphetamine within the human body. We report a 25-year-old woman 
with severe depression who died due to a fatal tranylcypromine overdose in 2016. She had been prescribed 
tranylcypromine one day previously and had no history of previous suicide attempts or substance abuse. The 
body was transferred to a forensic medicine department in Tehran, Iran for the autopsy. A urine sample was 
positive for tranylcypromine, amphetamine and methamphetamine using gas chromatography/mass spectrometry 
after derivatisation with heptafluorobutyric acid. As amphetamines were present in the urine sample, it was 
assumed that the tranylcypromine had been converted to amphetamines metabolically. As such, it is possible that 
the legitimate use of certain prescription drugs may complicate the interpretation of test results for illegal drugs.
Keywords: Tranylcypromine; Amphetamine; Metabolism; Forensic Toxicology; Substance Abuse Detection; Case 
Report; Iran.
امللخ�ص: عقار الرتانيل�سيربومني امل�ساد لالكتئاب هو من فئة مثبطات مونو اأمني اأوك�سيديز و ي�سابه هيكليا االأمفتامني. توجد تقارير 
خمتلفة لعملية اأي�س الرتانيل �سيربومني اثناء حتويله اإىل اأمفيتامني و ميثا مفيتامني. هذا تقرير عن اإمراأة يبلغ عمرها 25 عاما كانت تعاين 
من االكتئاب ال�سديد توفت ب�سبب تناول جرعة زائدة مميتة من عقار الرتانيل �سيربومني عام 2016م. مت و�سف عقار الرتانيل �سيربومني لها 
قبل وفاتها بيوم واحد. اأظهر التاريخ املر�سي لها عدم وجود �سابقة انتحار اأو ادمان املخدرات. مت نقل اجلثمان اإىل ق�سم الطب ال�رشعي يف 
طهران-اإيران بغر�س الت�رشيح. بعد ا�ستقاق عينة البول مت الك�سف عن وجود الرتانيل �سيربومني، ميثا مفيتامني و االأميفتامني با�ستخدام 
طريقة الكروماتوجرايف الغازي/التحليل الطيفي. وقد افرت�س اأن االأمفيتامني ناجت عن اأي�س عقار الرتانيل �سيربومني. بناء على هذا فاأن 
ا�ستعمال بع�س االأدوية املرخ�سة قد ي�سبب م�ساكل يف تاأويل نتائج فح�س العقاقري املمنوعة.
الكلمات املفتاحية: ترانيل �سيربومني؛ اأمفيتامني؛ اأي�س؛ علم ال�سموم ال�رشعي؛ التعرف على ادمان املواد؛ تقرير حالة؛ اإيران.
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contribution of amphetamine to the pharmacological 
response should not be underestimated.5 
Reliable laboratory methods of detecting drugs 
such as tranylcypromine and amphetamine-type 
stimulants have been previously validated using 
various parameters, such as selectivity, linearity, 
accuracy and precision, limits of detection, limits 
of quantitation and recovery.6,7 Most countries 
legally restrict the recreational use of amphetamines 
and categorise this class of drugs under controlled 
substances.8 Despite this, the use of amphetamine-
type stimulants has become increasingly popular, 
particularly among young people;7 it is therefore 
important to accurately interpret any forensic toxic-
ology results in both living and deceased patients. In 
addition, physicians should be aware of the possibility 
Tranylcypromine is an irreversible non-selective monoamine oxidase inhibitor often prescribed as an antidepressant.1,2 Tranyl-
cypromine is a well-known structural analogue of 
amphetamine to which a cyclopropyl ring is fused; 
however, there is some evidence that suggests the 
cyclopropyl ring undergoes metabolic cleavage to 
form three metabolites: amphetamine, 1-amino-2-
phenylpropane and 1-amino-3-phenylpropane.1,3 This 
metabolic formation of amphetamine is responsible 
for the therapeutic effects of tranylcypromine as 
well as those that occur following withdrawal.1–4 A 
therapeutic dose of tranylcypromine constitutes 
30 mg per day, usually given in divided doses. While 
this amount of the drug is unlikely to produce a marked 
degree of amphetamine-like central activity, the 
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were analysed quantitatively to detect ethanol and 
methanol via headspace gas chromatography using 
the 6890N Network Gas Chromatograph (Agilent 
Technologies Inc.) equipped with a flame ionisation 
detector. A spectrophotometer (Series 9000, Cecil 
Instruments, Peterborough, UK) was used to analyse 
carboxyhaemoglobin levels. 
Amphetamine and methamphetamine levels in 
the urine sample were analysed using the derivatisation 
reagent heptafluorobutyric acid (HFBA).6,7 A total of 
1 mL of urine was centrifuged for five minutes at 
9,000 rpm and the supernatant was separated. The 
sample was alkalinised by adding 0.5 M of potassium 
hydroxide and the pH was adjusted to 11–12. 
Amphetamine and methamphetamine were extracted 
by adding 3 mL of n-hexane and shaking the sample 
for 20 minutes before immersing it in a freezing 
bath to separate the organic compounds. A freezing 
bath was used instead of more common methods, 
such as a separatory funnel, because of the low 
volume of urine in the sample, which made it more 
difficult to distinguish between aqueous and organic 
phases. In order to avoid losing volatile analytes such 
as amphetamine and methamphetamine, a small 
amount of hydrochloric acid (HCl) was added before 
the evaporation stage as a keeper solvent.9 A total of 
100 μL of methanol and HCl (at a ratio of 99:1 v/v) was 
added to the medium and the solvent was completely 
evaporated under a gentle stream of nitrogen. The 
extract was reconstituted with 100 μL of n-heptane 
and vortexed for one minute. For derivatisation, 25 μL 
of HFBA was added and the mixture was vortexed for 
three minutes. The excess HFBA was deactivated by 
adding 500 μL of sodium bicarbonate and vortexing 
the mixture for one minute. The mixture was again 
placed in a freezing bath and the organic layer was 
separated for GCMS analysis.
Instrument control and data acquisition was 
performed using ChemStation software, Version G20-
70BA (Agilent Technologies Inc.) with a 5-ms capillary 
column at a length of 30 m, internal diameter of 0.25 mm 
and film thickness of 0.25 mm. Gas chromatographic 
conditions were set as follows. Helium of 99.99% 
purity was used as a carrier gas with a constant flow 
rate of 1.5 mL per minute. The inlet temperature was 
set at 250 °C and a volume of 1 mL was used for the 
splitless injection. The column temperature was set at 
90 °C for one minute and then increased at a rate of 
20 °C per minute to 280 °C for five minutes. Mass 
source and quadrupole temperatures were fixed at 
230 °C and 150 °C, respectively. The ion source was 
operated by electron impact at 70 eV in selected ion 
monitoring and full-scan mode with a scan range of 
that certain therapeutic prescription drugs—such 
as tranylcypromine—may be metabolised to illegal 
drugs like amphetamines in humans. This report 
describes a case of a fatal overdose involving tranyl- 
cypromine, wherein tranylcypromine, methamphet-
amine and amphetamine were detected postmortem.
Case Report
A 25-year-old woman was found dead in her bed in 
Tehran, Iran, in 2016. She had last been seen alive 
five hours previously. She had a history of severe 
depression, but there was no record of any prior suicide 
attempts. In addition, her relatives reported that she 
had no history of substance abuse. One day before her 
death, she had been prescribed tranylcypromine by her 
psychiatrist, to be taken twice a day. Upon investigation 
of the scene of death, the police found a bottle of 100 
tablets containing 10 mg of tranylcypromine each 
beside her bed, of which 19 tablets appeared to be 
missing. The corpse was subsequently transferred to 
the Department of Forensic Medicine at the Legal 
Medicine Organization in Tehran for an autopsy in 
order to determine the cause of death.
The autopsy revealed no external injuries to the 
body. The woman weighed 60 kg and her height was 
163 cm. The internal organs were normal in size and 
shape. The stomach contained approximately 300 mL 
of fluid and some digested food. Under the supervision 
of a forensic specialist, biological specimens were 
collected, including liver, stomach content, vitreous 
humour, blood and bile samples. Solid tissue, such as 
that of the liver, was minced and homogenised with two 
parts of distilled water. Liquid-liquid extraction with 
chloroform and isopropanol (at 80:20 volume/volume 
percent [v/v]) was used to prepare the biological 
matrices before analysis. Extraction products were 
subsequently analysed via thin-layer chromatography, 
high-performance liquid chromatography (HPLC) 
and gas chromatography/mass spectrometry (GCMS). 
Thin-layer chromatography was performed with 
20 x 20 cm pre-coated aluminium sheets of 0.25 mm 
silica gel layer thickness with an ultraviolet fluorescent 
indicator (ALUGRAM® Xtra SIL G SIL UV254, 
Macherey-Nagel Gmbh, Düren, Germany) whereas 
HPLC was performed with a diode array detector 
using a Eurospher II 100-5 C18 column of 250 mm 
x 4.6 mm at 5 μm particle size and 100 Å pore size 
(Knauer, Berlin, Germany) with a pump (Smartline 
1000, Knauer). GCMS was performed using the 
7890A Gas Chromatograph and 5975C Mass Selective 
Detector (Agilent Technologies Inc., Santa Clara, 
California, USA). Blood and vitreous humour samples 
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Figure 1: Chromatogram of amphetamine, methamphetamine and tranylcypromine derivatised with heptafluorobutyric 
acid as detected in the urine of a 25-year-old woman who died due to a fatal tranylcypromine overdose.
HFB = heptafluorobutyric acid.
 
Figure 2: Mass spectra graphs of (A) amphetamine, (B) methamphetamine and (C) tranylcypromine derivatised with 
heptafluorobutyric acid as detected in the urine of a 25-year-old woman who died due to a fatal tranylcypromine overdose.
40–500 m/z. The toxicological results of the urine 
sample were negative for all drugs except for 
tranylcypromine, amphetamine and methamphet-
amine [Figures 1 and 2]. Tranylcypromine was also 
detected in the stomach contents. 
Discussion 
Among humans, severe intoxication can occur if the 
maximum daily dose of 60 mg of tranylcypromine 
is exceeded.1 Tranylcypromine-related deaths can 
be attributed to either an overdose due to misuse 
of the drug by the patient or to a hypertensive crisis 
leading to a cerebrovascular accident as a result of 
a therapeutic dose.10 Although tranylcypromine 
has been commercially available for many years, 
little is yet known of its metabolic pathway. Baker 
et al. reported finding N- acetylcysteine and ring-
hydroxylated metabolites in the brain of a rat 
following the administration of tranylcypromine.11 
However, there are conflicting reports as to whether 
tranylcypromine is metabolised to amphetamine and 
methamphetamine.3,4,8,12,13
In the current case, tranylcypromine was 
detected in combination with amphetamine and 
methamphetamine in the urine sample of a fatal 
overdose case. One possible explanation for the 
presence of amphetamines in such postmortem 
specimens is the biotransformation of tranylcy-
promine to amphetamine and methamphetamine 
within the human body. Crifasi et al. similarly 
reported the presence of metabolic products, such 
as amphetamine and methamphetamine, in the body 
of a tranylcypromine overdose case.14 Youdim et al. 
also detected amphetamine in the plasma of a 
patient who had overdosed on tranylcypromine.4 
However, Sherry et al. found no amphetamines 
in biological samples obtained from both rats and 
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in Iran, it was not possible to publish a case series on 
this topic.
Conclusion
The present report described a fatal tranylcypromine 
overdose case in which methamphetamine and 
amphetamine were found in the urine samples of 
a young woman with no history of substance abuse. 
In this case, it is conceivable that the tranylcy-
promine underwent a metabolic opening of the 
cyclopropyl ring to produce amphetamine and meth- 
amphetamine. However, further investigation is 
needed to determine the exact metabolic pathway 
of tranylcypromine in the human body. This would 
provide valuable evidence when interpreting forensic 
toxicology results so as to ascertain whether the 
presence of methamphetamine and amphetamine 
indicate the legitimate use of a prescription drug or, 
alternatively, illegal substance abuse.
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